Royalty Pharma plc
http://www.royaltypharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Royalty Pharma plc
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.
PureTech Cashes In On Promise Of Karuna Schizophrenia Drug
Karuna’s KarXT could be the first new mechanism for treating schizophrenia approved in more than 50 years and founder PureTech is tapping into that promise by linking up with Royalty Pharma and boosting its cashpile.
Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.
Hemab Raises $135m To Advance Clinical Strategy In Bleeding And Thrombotic Disorders
Hemab’s series B financing will fund its lead program, currently in Phase I/II for Glanzmann thrombasthenia, as it moves into pivotal testing plus at least one other asset heading into the clinic.
Company Information
- Industry
- Miscellaneous
- Other Names / Subsidiaries
-
- Cypress Bioscience, Inc. (Cellatope Corporation
- Proprius Pharmaceuticals, Inc.)
- Ramius LLC
- Royalty Pharma AG
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice